Linagliptin: A comprehensive profile.

Q1 Pharmacology, Toxicology and Pharmaceutics

Profiles of drug substances, excipients, and related methodology Pub Date : 2025-01-01 Epub Date: 2025-01-09 DOI:10.1016/bs.podrm.2024.10.001

Mohamed Fawzy Kabil, Jude Majed Lababidi, Hassan Mohamed El-Said Azzazy

引用次数: 0

Abstract

Linagliptin (LINA) is the first dipeptidyl peptidase IV (DPP-IV) inhibitor that could be administered orally to control hyperglycemia. It is indicated for controlling adult blood sugar levels that are diagnosed with diabetes mellitus type II. The current chapter provides a complete review of LINA including nomenclature, physiochemical characteristics, synthesis, and thermal analysis. Additionally, different analytical techniques used for quantitative and qualitative determination of LINA are presented.

查看原文本刊更多论文

利格列汀：综合概况。

利格列汀（LINA）是第一个可以口服控制高血糖的二肽基肽酶IV （DPP-IV）抑制剂。适用于控制II型糖尿病成人血糖水平。本章提供了一个完整的审查LINA包括命名法，理化特性，合成和热分析。此外，还介绍了用于LINA定量和定性测定的不同分析技术。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊